ANG Lifesciences (540694)

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 1/2 · Dividend: 0/1

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

Let me apply the same lens I use with any business: what is the durable earning power, and how much am I paying for it? ANG Lifesciences gives me no positive earnings to underwrite. With a market cap of ₹66 crore and latest quarter sales of ₹19 crore that still produced a ₹5 crore loss, this is a company that is currently destroying value. The annual sales decline of 24.26% reinforces that. The reported profit growth of 8.48% is a small consolation, but a near-zero base can produce misleading percentages. Book value is ₹58.10 per share, so the stock at ₹50.92 is priced at 0.88 times book. That looks like an asset play until you notice ROE of -10.59% and ROCE of -4.18%. A book value that earns negative returns is a shrinking asset; the buffer can melt away if losses continue. The Piotroski score of 5 out of 9 is middling and does not tell me the business is recovering. There is no dividend, debt/equity is unavailable, and promoter holding is not disclosed, so an outside shareholder faces a lack of transparency. The 52-week range of ₹17.63 to ₹50.92 shows the stock has already moved up sharply, but price action is not value. A Graham disciple buys a bargain only when assets are real, management is honest, and there is a catalyst. I see no proof of that here. This may one day become a turnaround, but I need to see stable sales, positive net profit, and improving returns on capital before risking our money. For now, the arithmetic does not convince me.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer